FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| Washington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

| OMB APPROVAL | | | | | | | | | |
|----------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average bu | ırden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Fruchtman Steven M | | | | 2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ONTX] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
|-------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------|-----------------------|---------------------|-------------------------------------|------------------|--------------------------|-------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------------|---------------------------------------|
| <u>Frucnti</u> | nan Stev | <u>en M</u> | | | | | | 21101 | <u> apeure</u> | <u> </u> | <u>c.</u> [01. | | | | X Directo | or | | 10% Ov | vner |
| (Last) | (F | irst) | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 08/02/2023 | | | | | | | helow) | | T PX | Other (s | | | |
| C/O ONCONOVA THERAPEUTICS, INC | | | | | | | | | | | | 1 | PRESIDENT, CHIEF EXECUTIVE OFF | | | | | | |
| 12 PENNS TRAIL | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | |
| (Street) | | | | | | | | | | | | | | | X Form | filed by One | e Repo | orting Perso | on |
| NEWTO | WN PA | A | 18940 | | | | | | | | | | | | Form to Person | | re thar | one Repo | orting |
| (City) | (S | tate) | (Zip) | | Ru | le í | 10b | 5-1(c) |) Trans | act | ion Inc | dicat | ion | | | | | | |
| | | | | | | | | | licate that a defense c | | | | | | tract, instruct on 10. | ion or writter | n plan t | hat is intend | ed to |
| | | Tab | le I - No | n-Deriv | ative | Sec | curit | ies Ac | quired, | Dis | posed o | of, or | Ben | eficial | ly Owne | d | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | Execution Date, | | Code (Instr. 5) | | rities Ad ed Of (D | cquirec) (Instr | I (A) or :. 3, 4 and | Benefic Owned | es ially Following | Form (D) o | n: Direct r Indirect estr. 4) | 7. Nature of Indirect Beneficial Ownership | | | | | |
| | | | | | | | | | Code | v | Amount | | (A) or (D) | Price | Reporte Transac (Instr. 3 | tion(s) | | | (Instr. 4) |
| Common Stock 08/ | | | 08/02 | 2/2023 | | | | М | | 12,56 | 67 A | | (1) | 53 | 53,044 | | D | | |
| Common Stock 08/03/ | | | ′2023 | | | F | | 4,74 | 4 D \$ | | \$1.0 | 1 48,300 | | D | | | | | |
| | | Т | | | | | | | uired, E s, option | | | | | | Owned | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any (Month/Da | n Date, | 4. Transac Code (In 8) | | | | 6. Date E: Expiratio (Month/D | n Date | • | 7. Title and Amount of Securities Underlying Derivative Se (Instr. 3 and 4 | | 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | ly D | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exercisal | ole E | Expiration Date | Title | 0 N | mount or lumber of Shares | | | | | |
| Restricted Stock Units | (1) | 08/02/2023 | | | M | | | 12,567 | (2) | | (2) | Comn | | 2,567 | \$0 | 12,567 | 7 | D | |

Explanation of Responses:

- ${\bf 1.}\ Restricted\ stock\ units\ convert\ into\ common\ stock\ on\ a\ one-for-one\ basis.$
- 2.0 On August 2,2021 the reporting person was granted 37,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

/s/ Mark Guerin, Attorney-in-

08/04/2023

<u>Fact</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.